Technical Analysis for CERE - Cerevel Therapeutics Holdings, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Gilligan's Island Sell Setup | Bearish Swing Setup | 2.77% | |
New 52 Week Closing High | Bullish | 2.77% | |
Pocket Pivot | Bullish Swing Setup | 2.77% | |
Volume Surge | Other | 2.77% | |
Calm After Storm | Range Contraction | 2.77% | |
Narrow Range Bar | Range Contraction | 2.77% | |
New 52 Week High | Strength | 2.77% | |
Parabolic Rise | Strength | 2.77% | |
Upper Bollinger Band Walk | Strength | 2.77% | |
New 52 Week Closing High | Bullish | 14.46% |
Alert | Time |
---|---|
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. |
Get a Trading Sidekick!
- Earnings date: 05/01/2024
Cerevel Therapeutics Holdings, Inc. Description
Cerevel Therapeutics Holdings, Inc. operates as a clinical-stage biopharmaceutical company engages in the development of various therapies for neuroscience diseases. Its products include CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase 1b multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase 2 proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a Phase 1 proof-of-principle trials in acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase 3 program for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase 1 single ascending dose trials for the treatment of substance use disorder (SUD). It is also involved in the development of various preclinical compounds for various neuroscience indications. The company was founded in 2018 and is headquartered in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Neuroscience Schizophrenia Dementia Epilepsy Seizure Medicinal Chemistry Dopamine Substance Use Disorder Taar1 Agonists
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 43.5898 |
52 Week Low | 19.59 |
Average Volume | 1,521,057 |
200-Day Moving Average | 31.90 |
50-Day Moving Average | 41.92 |
20-Day Moving Average | 41.91 |
10-Day Moving Average | 42.34 |
Average True Range | 0.36 |
RSI (14) | 57.81 |
ADX | 21.94 |
+DI | 22.30 |
-DI | 16.56 |
Chandelier Exit (Long, 3 ATRs) | 41.71 |
Chandelier Exit (Short, 3 ATRs) | 41.88 |
Upper Bollinger Bands | 42.96 |
Lower Bollinger Band | 40.87 |
Percent B (%b) | 0.67 |
BandWidth | 5.00 |
MACD Line | 0.22 |
MACD Signal Line | 0.19 |
MACD Histogram | 0.0291 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 42.68 | ||||
Resistance 3 (R3) | 42.67 | 42.52 | 42.61 | ||
Resistance 2 (R2) | 42.52 | 42.42 | 42.53 | 42.58 | |
Resistance 1 (R1) | 42.40 | 42.36 | 42.33 | 42.41 | 42.56 |
Pivot Point | 42.25 | 42.25 | 42.22 | 42.26 | 42.25 |
Support 1 (S1) | 42.13 | 42.15 | 42.06 | 42.14 | 41.98 |
Support 2 (S2) | 41.98 | 42.09 | 41.99 | 41.96 | |
Support 3 (S3) | 41.86 | 41.98 | 41.93 | ||
Support 4 (S4) | 41.87 |